E-DRUG: Cipla To Provide AIDS Drug To Cameroon at USD 350 pp/yr
----------------------------------------------------------------------------
----
[Combivir and Epivir of GSK seem to be the only patent protected ARVs in
cameroun. All other ARVs are apparently not protected, allowing generic
suppliers access to the market, provided they have registered their generics
as good quality products.
In Nigeria Roche also patented Hivid in addition to the 2 GSK drugs, but no
other ARVs.
In Algeria no ARV appears to be patent protected.
African countries should check the patent status of their ARVs, as most of
them are NOT
protected in their countries.
Crossposted from healthGap with thanks. Copied as fair use. NN]
INDIA PRESS: Cipla To Provide AIDS Drug To Cameroon
07/27/2001
Dow Jones Asian Equities Report
NEW DELHI -(Dow Jones)- Cipla Ltd. (P.CIP) has signed an agreement
with the Cameroon government to supply its AIDS triple therapy at
$350 per patient a year, according to the Financial Express.
The Indian pharmaceutical company signed a similar deal with the
Nigerian government and negotiations are underway with Algeria, said
the local daily.
The therapy is a three-drug combination of AIDS medicines.
Cipla said it is willing to sell AIDS drugs "at cost" to any
government that distributes them free to the people.
Joint Managing Director Amar Lulla said the Cameroon deal is expected
to be worth half a million dollars every three or four months,
reports the daily.
Web Site: http://www.financialexpress.com
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Information and archive http://satellife.healthnet.org/programs/edrug.html
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.